Mesoblast
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Its global presence extends across the United States, Australia, Si...
Latest News
1 day ago · globenewswire.com
Mesoblast Showcased at ASX Premier Investor Day EventNEW YORK, Nov. 15, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it was highlighted at the Australian Securities Exchange (ASX) Investor Day in Melbourne at the session titled “Meet the CEO: Inside Australia's Listed Companies.”
4 days ago · marketbeat.com
Mesoblast Posts $115 Million in Revenue, Sets Sights on 2027 Back Pain Trial ReadoutMesoblast NASDAQ: MESO reported $115 million in net revenue for fiscal 2026 and said it expects a pivotal trial readout for its experimental chronic low back pain treatment around midyear to the third quarter of calendar 2027.
12 days ago · globenewswire.com
Use Of Ryoncil First Line After Steroids For Pediatric Acute Graft Versus Host Disease Highlighted In Key Opinion Leader WebinarNEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that it hosted a key opinion leader webinar this week titled “The Graft-versus-Host Disease Exchange - Expert Perspectives on Evolving Clinical Practice” with leading pediatric transplant and cellular-therapy specialist Dr. Susan Prockop, Associate Professor, Harvard Medical School; Attending Physician & Director, Boston Children's Hospital. Dr. Prockop provided an overview of Ryoncil® (remestemcel-L-rknd)1 as a new treatment paradigm in the management of acute graft-versus-host disease, its use as first line after steroids, highlighted case studies, and discussed results from pivotal trials.
15 days ago · globenewswire.com
Mesoblast Board ChangesNEW YORK, Nov. 01, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced rotational changes and retirement of certain members of its Board, and reiterated its intention to add new members with the requisite global commercial experience in the biopharmaceutical sector in line with its next phase of commercial delivery and growth.
19 days ago · globenewswire.com
Activity Report for Quarter Ended September 30, 2026 (Appendix 4C)NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided its activity report for the first fiscal quarter ended September 30, 2026.
29 days ago · seekingalpha.com
Mesoblast: Ryoncil Helps Fund Rexlemestrocel-L For Back PainMesoblast's Ryoncil provides commercial validation for its cell-therapy platform while helping finance additional development. Ryoncil's ongoing growth should also help finance MESO's remaining pipeline, in particular Rexlemestrocel-L. You see, Rexlemestrocel-L could give MESO another larger TAM as a back-pain franchise if its pivotal data support approval.
2 months ago · globenewswire.com
Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil ProductNEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received approval from the United States Food and Drug Administration (FDA) to implement a new potency assay, T-cell Proliferation Inhibition BioAssay (TIBA), for release and stability monitoring of all new commercial product lots of its FDA-approved mesenchymal stromal cell (MSC) product Ryoncil® (remestemcel-L-rknd).
3 months ago · seekingalpha.com
Mesoblast Limited (MESO) Q4 2026 Earnings Call TranscriptMesoblast Limited (MESO) Q4 2026 Earnings Call Transcript
3 months ago · globenewswire.com
Mesoblast Reports Substantial Revenue Growth to US$120MRYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment Financial Results and Operational Update for Full Year Ended June 30, 2026 NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026). Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026.
3 months ago · marketbeat.com
Mesoblast H2 Earnings Call HighlightsMesoblast NASDAQ: MESO reported $115 million in net revenue for fiscal 2026, its first full year of commercial sales for RYONCIL, the company's FDA-approved allogeneic mesenchymal stromal cell therapy for children with steroid-refractory acute graft-versus-host disease, or GVHD.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove MESO